This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 2 of 17 for:    Hemifacial Spasm

Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm

This study has been completed.
Information provided by:
Ipsen Identifier:
First received: January 12, 2006
Last updated: July 23, 2007
Last verified: July 2007
To compare the effectiveness and safety of Dysport® with the domestic Botulinum Toxin Type A (manufactured by Lanzhou Biologic Product Institute, P.R. China) for the treatment of hemifacial spasm.

Condition Intervention Phase
Hemifacial Spasm Drug: Botulinum type A toxin (Dysport®) - one single injection Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: A Phase III, Multicentre, Randomised, Assessor-Blind, Parallel Groups, Reference Drug Controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection of Dysport® for the Treatment of Hemifacial Spasm

Resource links provided by NLM:

Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels) [ Time Frame: At the end of week 4 ]

Secondary Outcome Measures:
  • Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels after medication) [ Time Frame: At the end of week 1 and 12 ]
  • Improvement degree of spasm (Jankovic scale) [ Time Frame: At the end of week 1, 4 and 12 ]
  • Assessment of efficacy by the subjects [ Time Frame: At the end of week 1, 4 and 12 ]

Estimated Enrollment: 348
Study Start Date: December 2005
Study Completion Date: January 2007

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient suffering from hemifacial spasm with at least 6 months duration (prior to visit 1)
  • Cohen scale ≥ to grade II

Exclusion Criteria:

  • Botulinum toxin type A treatment history within last 16 weeks prior to visit 1
  • Hemifacial spasm secondary to facial palsy
  • Previous alcohol or phenol injections or surgical therapy of the facial muscles
  • Requirement for botulinum toxin injection to site(s) of the body other than in this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00276315

Neurology Department, Peking Union Medical College Hospital
Beijing, China, 100730
Neurology Department, Guangdong Provincial People's Hospital
Guangdong, China, 510080
Neurology Department, Sir Run Run Shaw Hospital, Zhejiang University
Hangzhou, China, 310016
Neurology Department, Shanghai Ruijin Hospital
Shanghai, China, 200025
Sponsors and Collaborators
Study Director: Jing-dong Ma, MD Ipsen
  More Information Identifier: NCT00276315     History of Changes
Other Study ID Numbers: A-38-52120-074
Study First Received: January 12, 2006
Last Updated: July 23, 2007

Additional relevant MeSH terms:
Hemifacial Spasm
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Mouth Diseases
Stomatognathic Diseases
Botulinum Toxins, Type A
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents processed this record on June 23, 2017